Fostering the development and rational use of new antibiotics: how a product development partnership could promote innovation and responsible access to new antibiotics

Technical consultation hosted by
Drugs for Neglected Diseases initiative and the World Health Organization
Geneva, Switzerland
8 - 9 December 2014

List of Participants

James Anderson
Director, European Partnerships, Government Affairs, Public Policy & Patient Advocacy
GlaxoSmithKline
London, United Kingdom

Manica Balasegaram
Executive Director, Access Campaign
Médecins Sans Frontières
Geneva, Switzerland

Richard Bergström
Director General
European Federation of Pharmaceutical Industries and Associations
Brussels, Belgium

Charles Clift
Senior Consulting Fellow and Chair, Medicines Patent Pool
Chatham House
London, United Kingdom

Marja Esveld
Senior Advisor International Research and Innovation
Ministry of Health, Welfare and Sport
Netherlands

Mark Kessel
Chairman of the Board
FIND
Geneva, Switzerland

Nadia Khelef
Senior Advisor for Global Affairs
Institut Pasteur
Paris, France

Ilona Kickbusch
Director Global Health Programme
Graduate Institute of International and Development Studies
Geneva, Switzerland
Björn Kümmel  
Federal Ministry of Health  
Germany  
Berlin, Germany

Joe Larsen  
Chief,  
Broad Spectrum Antimicrobials Program at the Biomedical Advanced Research Development Authority (BARDA)  
Washington, DC, USA

Greg Perry  
Executive Director Medicines Patent Pool  
Geneva, Switzerland

Malebona Precious Matsoso  
Director General  
South African National Department of Health  
Pretoria, South Africa

Colin McIff  
Health attaché to the United Nations  
US State Department  
Geneva, Switzerland

Carlos Morel  
Director Center for Technological Development in Health  
Oswaldo Cruz Foundation (FIOCRUZ)  
Rio de Janeiro, Brazil

Manos Perros  
Head of Infection Research and Early Development  
Astra Zeneca  
Boston, Massachusetts, USA

John-Arne Røttingen  
Director, Division of Infectious Disease Control  
Norwegian Institute of Public Health  
Oslo, Norway

Anthony So  
Director Program on Global Health and Technology Access  
Duke University  
Durham, NC, United States

Antony Taubman  
Director Intellectual Property Division  
World Trade Organization  
Geneva, Switzerland

Arjon Van-Hengel  
Scientific Officer  
European Commission  
Brussels, Belgium

Viviana Tellez Munoz  
Manager, Innovation and Access to Knowledge Programme
Geneva, Switzerland

**Drugs for Neglected Diseases initiative (DNDi):**

Bernard Pécoul
Executive Director
Geneva, Switzerland

Jean-François Alesandrini
Director Advocacy, Fundraising and Communication
Geneva, Switzerland

Graeme Bilbe
Director Research and Development
Geneva, Switzerland

Jean-Pierre Paccaud
Business Development Director
Geneva, Switzerland

**World Health Organization:**

Marie-Paule Kieny
Assistant Director General Health Systems and Innovation
Geneva, Switzerland

Zafar Mirza
Coordinator, Public Health, Innovation and Intellectual Property
Geneva, Switzerland

Peter Beyer
Senior Advisor Public Health, Innovation and Intellectual Property
Geneva, Switzerland

Charles Penn
Coordinator Antimicrobial Resistance
Geneva, Switzerland

Taghreed Adam
Scientist, Research and Knowledge Translation
Geneva, Switzerland

Meghana Sharafudeen
Technical Officer, Public Health, Innovation and Intellectual Property
Geneva, Switzerland

**Invited, but unable to attend:**

Maged Al-Sherbiny
Assistant Minister for Scientific Research
Ministry of Higher Education and Scientific Research
Cairo, Egypt

Hala Audi
Head of the Review Team
Review on Antimicrobial Resistance
London, United Kingdom

Anna Halén
Health Attaché
Sweden
Geneva, Switzerland

Paul Herrling
Former Head of Corporate Research at Novartis
Basel, Switzerland

Amanda Jezek
Vice President of Public Policy and Government Relations
Infectious Diseases Society of America (IDSA)
United States

Vijay Raghavan
Secretary
Department of Biotechnology
New Dehli, India

David Reddy
Chief Executive Officer
Medicines for Malaria Venture (MMV)
Geneva, Switzerland

Richard N. Seabrook
Head of Business Development Innovations
The Wellcome Trust
London, United Kingdom

Melvin Spigelman
President and Chief Executive Officer
Global Alliance for TB Drug Development (TB Alliance)
Geneva, Switzerland

Viroj Tangcharoensathien
Senior Expert
Ministry of Public Health
Bangkok, Thailand

Marcel Tanner
Director, Swiss Tropical and Public Health Institute (Swiss TPH)
Basel, Switzerland

Yonghong Xiao
Professor Principal Investigator, State Key Laboratory for Diagnosis & Treatment of Infectious Diseases
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China